Wednesday, 13 Nov 2019

RA/Inflammatory arthritis

Datesort ascending Type Title Save
13 Nov 2019 ACR Video Inflammatory Arthritis Persists After Immunotherapy Cessation: Dr. David Liew
13 Nov 2019 ACR Video Studies on the Changing Face of RA: Dr. Janet Pope
13 Nov 2019 ACR Video Panel Presentation: Rheumatoid Arthritis
13 Nov 2019 ACR Video Safety of Methotrexate (The CIRT Trial): Dr. Jack Cush
12 Nov 2019 ACR Video Studies on the Changing Face of RA: Dr. Janet Pope
11 Nov 2019 ACR Video The Risk RA Prospective Study: Dr. Jonathan Kay
10 Nov 2019 Slide of the day Adult Stills Disease & Febrile Disorders
10 Nov 2019 ACR Video Antimalarials in RA: Dr. Janet Pope
07 Nov 2019 News In RA, Activity Protects Cognition
01 Nov 2019 Social Canadian analysis of 1,183 newly diagnosed JIA - the incidence of uveitis was 2.8% per year. In multivariable analysis, the only independent risk factors were age <7 years at JIA diagnosis (HR 8.3) and +ANA (HR 3.2).
31 Oct 2019 News The Global Burden of Rheumatoid Arthritis 2017
31 Oct 2019 News Outcomes in Juvenile Idiopathic Arthritis
31 Oct 2019 Social Metanalysis of multi‐biomarker disease activity (MBDA or Vectra) score & RA disease activity looked at 22 studies showing modest correlations w/ DAS28‐CRP (r 0.41) & DAS28‐ESR (r 0.48), but weaker correlations with SDAI, CDA (r 0.26) and RAPID3 (r 0.23)
30 Oct 2019 Social One year outcomes (pain & function) following total hip or knee arthroplasty in 122 #RA pts followed by HSS - outcomes were predicted by disease activity (higher activity increased risk of worse pain & function), not predited by post-operative flares.
28 Oct 2019 Social Claims study of 253K csDMARD #RA showed switching to biologics/targeted synthetic DMARDs had increased risk of venous thromboembolism (HR 1.36 ;1.16, 1.58); Compared to 1st b/tsDMARDuse; VTE was higher for 1st (1.35) and 2nd b/tsDMARD switchers (1.48)
23 Oct 2019 Social CARRA study of 50 pts with juvenile localized scleroderma treated with either MTX (oral or IV) or steroids and 75% were improved by skin outcomes at 48 wks - medication intolerance in 14%) and treatment failure in 25%. Controlled RCT is needed.
23 Oct 2019 Social CORRONA Registry - 409 biologic naive, #RA pts followed every 6 mos - at baseline half (54%) had moderate-high disease activity - yet only 29% had a change in treatment. DMARD changes more likely in your, shorter duration, high dz activity/pain/fatigue
22 Oct 2019 Social #RA study shows that from 2014 to 2018, the number of malignant tumors that could be treated with immune checkpoint inhibitors has grown from 0 to 7%. Knowledge of ICI immune related adverse events is essential for rheumatologists
21 Oct 2019 News Comorbidities Increase in Importance in RA
21 Oct 2019 Social Retrospective study of 102 RA patients interstitial lung dz, and 52% had progressive fibrosing-ILD; these were associated with increased mortality. Predictors of mortality were DLco and high titres IgM rheumatoid factor